Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shareholders Approve Merger With Precipio Dx

NEW YORK (GenomeWeb) – Transgenomic today announced its shareholders have approved the previously announced planed merger with Precipio Diagnostics.

More than 90 percent of votes cast by Transgenomic's shareholders gave the go-ahead to the deal at a special shareholders meeting held on Monday, the firm said. Additionally, more than 95 percent of Precipio's voting members approved the merger.

Upon completion of the transaction, privately held Precipio will become a wholly owned subsidiary of Transgenomic. Shares of the new firm, to be called Precipio Inc., will be listed on the Nasdaq under ticker symbol PRPO.

The merger was announced in October. At the time, Transgenomic said the new company would receive up to $7 million from a private placement of preferred convertible securities led by BV Advisory Partners simultaneous to completion of the merger.

Transgenomic added today that it and Precipio continue working to close the combined company's $7 million private placement of preferred convertible securities, and a conversion of all outstanding secured debt into the combined company's preferred convertible securities.

Precipio Founder and CEO Ilan Danieli will be the CEO of the new firm. 

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.